Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
LPL contributes profoundly to physiologic lipoprotein metabolism and to tissue-specific substrate delivery and utilization (1). Perturbed LPL activity affects global energy balance, insulin action, body weight maintenance, and CVD risk; the latter alluded to by contemporary human genetic studies. LPL is the pivotal rate-limiting mediator of hydrolysis of core TGs from TG-rich lipoproteins, particularly chylomicrons and VLDL (2, 3). The products of LPL-mediated catalysis, such as fatty acids and monoacylglycerol, are handled differentially at local sites depending on the global hormonal and nutritional milieu, and local energy needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apo C-II is a cofactor for LPL91,92”
From Clinical review on triglycerides (2020) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“However, apo C-II has not been genetically validated as a target for ASCVD.91”
From Clinical review on triglycerides (2020) · cites this paper as [91]
In the citing paper
“Finally, angiopoietin-like protein 4 (ANGPTL4) regulates LPL activity, analogous to ANGPTL3, but its mechanism is incompletely defined.91,97,98”
From Clinical review on triglycerides (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 3×
“Loss of apoA-V function is positively correlated with elevated plasma TG and increased CHD risk (44, 45).”
BackgroundLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 1×
“able apolipoprotein discovered bioinformatically (42),”
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · cited 1×
““familial combined hypolipidemia” or “familial hypobetalipoproteinemia type 2” (18, 49).”
BackgroundLipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741 · cited 1×
“LPL contributes profoundly to physiologic lipoprotein metabolism and to tissue-specific substrate delivery and utilization (1).”
BackgroundTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716 · cited 1×
“Another common functional APOA5 variant, namely the −1131C>T promoter variant, was associated with increased TG, reduced HDL cholesterol, and increased CHD risk in a meta-analysis of 101 studies (46).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650 · cited 2×
“Loss of apoA-V function is positively correlated with elevated plasma TG and increased CHD risk (44, 45).”
BackgroundSelf-citationPhysiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550 · cited 6×
“In contrast, common small-effect LPL loss-of-function variants in the general population are associated with milder increases in plasma TGs, due in part to impaired clearance of VLDL (5).”
BackgroundInfluentialHypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539 · cited 1×
“Transgenic overexpression of human APOC3 in mice is associated with severe hypertriglyceridemia (32), while targeted deletion of murine Apoc3 is associated with low TG and protection from postprandial hypertriglyceridemia (33).”
BackgroundAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · cited 2×
“Although earlier studies could not definitively tie this variant to cardioprotection (55), recent genetic findings clearly make this link (10, 53).”
BackgroundCoding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462 · cited 1×
“Also, there are a few ultra-rare apoE protein coding variants that can have dominant effects on the lipid phenotype, also with an associated increased CHD risk (29).”
BackgroundSelf-citationExcess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
Self-citationAngptl3 regulates lipid metabolism in mice
Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., & Furukawa, H. (2002) · Nature Genetics · doi:10.1038/ng814 · Cited by 379 · cited 1×
“as the causative gene explaining low plasma TG levels in KK/San mice (48).”
BackgroundChylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356 · cited 2×
“The central nonredundant role of basal LPL mass and activity in directing intravascular hydrolysis of TG-rich lipoproteins is underscored by the causative role of very rare homozygous loss-of-function variants in the LPL gene in patients with severe hypertriglyceridemia (essentially chylomicronemia) and increased risk…”
BackgroundSelf-citationBiochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348 · cited 2×
“The reader is referred to the beautiful work from Young (15) in defining the structure and function of this fascinating protein.”
BackgroundApolipoprotein E isoforms and lipoprotein metabolism
Phillips, M. C. (2014) · IUBMB Life · doi:10.1002/iub.1314 · Cited by 328 · cited 1×
“TG-rich lipoproteins, their remnants, and HDL (25).”
Peloso, G. M., Auer, P. L., Bis, J. C., Voorman, A., Morrison, A. C., Stitziel, N. O., Brody, J. A., Khetarpal, S. A., Crosby, J. R., Fornage, M., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.01.009 · Cited by 317 · cited 1×
“1%) was associated with reduced TG and increased HDL cholesterol, but not with protection from CHD (57).”
BackgroundWang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D. M., Cohen, J. C., & Hobbs, H. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315292110 · Cited by 317 · cited 1×
“Mice lacking ANGPTL8 had lower TG levels, associated with both reduced VLDL secretion and increased LPL activity, indicating that ANGPTL8 plays a key role in the metabolic transition between fasting and refeeding; it might be required to direct fatty acids to adipose tissue for storage in the fed state (56).”
BackgroundMaeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · cited 1×
“Transgenic overexpression of human APOC3 in mice is associated with severe hypertriglyceridemia (32), while targeted deletion of murine Apoc3 is associated with low TG and protection from postprandial hypertriglyceridemia (33).”
BackgroundBenlian, P., De Gennes, J. L., Foubert, L., Zhang, H., Gagné, S. E., & Hayden, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351203 · Cited by 297
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278 · cited 1×
“Common variants in APOC3, particularly those in the promoter associated with failure to downregulate in the presence of insulin (37), have been associated with”
BackgroundApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274 · cited 1×
“This now appears to be inhibition by apoC-III of receptor-mediated hepatic clearance of TG-rich lipoproteins (41).”
BackgroundHelgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., Jonasdottir, A., Kristjansson, H., Sulem, P., Oddsson, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3561 · Cited by 254 · cited 3×
“6% reduction in plasma TG, but with no change in CHD risk (18).”
BackgroundThe ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking
Zhang, R. (2016) · Open Biology · doi:10.1098/rsob.150272 · Cited by 219 · cited 4×
“ANGPTL4 was initially identified as a peroxisome proliferator-activated receptor-dependent fasting-induced ANGPTL family member that inhibits LPL activity in an adipocyte-specific manner (47, 50, 51).”
BackgroundInfluentialJepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253757 · Cited by 218 · cited 1×
“First, it may be that plasma TGs are not the direct causative agent and may merely serve as an indirect marker for causal factors, such as the cholesterol content of atherogenic remnants, that are not measured clinically or epidemiologically (58); different gene products with the same impact on TG levels may have diff…”
BackgroundRegulation of lipoprotein lipase by Angptl4
Dijk, W., & Kersten, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.005 · Cited by 198 · cited 1×
“ANGPTL4 was initially identified as a peroxisome proliferator-activated receptor-dependent fasting-induced ANGPTL family member that inhibits LPL activity in an adipocyte-specific manner (47, 50, 51).”
BackgroundYlä-Herttuala, S., Lipton, B. A., Rosenfeld, M. E., Goldberg, I. J., Steinberg, D., & Witztum, J. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10143 · Cited by 196 · cited 1×
“remnants, which would then have more rapid uptake into macrophages, mediating foam cell formation (59); however, such a mechanism would be independent of effects”
BackgroundRegulation of lipid metabolism by angiopoietin-like proteins
Dijk, W., & Kersten, S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000290 · Cited by 192 · cited 3×
“ANGPTL4 was initially identified as a peroxisome proliferator-activated receptor-dependent fasting-induced ANGPTL family member that inhibits LPL activity in an adipocyte-specific manner (47, 50, 51).”
BackgroundRole of lipoprotein lipase in lipid metabolism
Olivecrona, G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000297 · Cited by 189 · cited 6×
“In contrast, common small-effect LPL loss-of-function variants in the general population are associated with milder increases in plasma TGs, due in part to impaired clearance of VLDL (5).”
BackgroundInfluentialApolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182 · cited 1×
“apoC-III, encoded by the APOC3 gene, is a constituent of several apoB-containing lipoproteins, including chylomicrons, VLDL and LDL, and also HDL particles (30).”
BackgroundApolipoprotein C-II and C-III levels in hyperlipoproteinemia
Schonfeld, G., George, P. K., Miller, J., Reilly, P., & Witztum, J. (1979) · Metabolism · doi:10.1016/0026-0495(79)90004-0 · Cited by 176 · cited 1×
“Perhaps paradoxically, apoC-II concentrations are elevated in hypertriglyceridemia (22); overexpression of apoC-II in”
BackgroundLarsson, M., Vorrsjö, E., Talmud, P., Lookene, A., & Olivecrona, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495366 · Cited by 169 · cited 2×
“Like apoC-I, apoC-III may inhibit LPL activity by preventing binding of LPL to the lipid-water interface of TG-rich lipoproteins and also by rendering LPL more susceptible to interference by ANGPTL4 (17).”
BackgroundInheritance of Apolipoprotein C-II Deficiency with Hypertriglyceridemia and Pancreatitis
Cox, D. W., Breckenridge, W. C., & Little, J. A. (1978) · New England Journal of Medicine · doi:10.1056/nejm197812282992601 · Cited by 152 · cited 1×
“cronemia phenotype that resembles LPL deficiency (21).”
Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.
Shachter, N. S., Hayek, T., Leff, T., Smith, J. D., Rosenberg, D. W., Walsh, A., Ramakrishnan, R., Goldberg, I. J., Ginsberg, H. N., & Breslow, J. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117151 · Cited by 139 · cited 1×
“(23), although an analogous situation in humans has not been observed.”
BackgroundA review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
Sagoo, G. S., Tatt, I., Salanti, G., Butterworth, A. S., Sarwar, N., van Maarle, M., Jukema, J. W., Wiman, B., Kastelein, J. J. P., Bennet, A. M., et al. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn235 · Cited by 132 · cited 1×
“variant that modestly lowers TGs and raises HDL cholesterol has repeatedly been associated with protection from CHD (9, 10).”
BackgroundCombined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
Shachter, N. S., Ebara, T., Ramakrishnan, R., Steiner, G., Breslow, J. L., Ginsberg, H. N., & Smith, J. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118857 · Cited by 117 · cited 1×
“The human APOC1 transgenic mouse has combined hyperlipidemia (16).”
BackgroundGPIHBP1, an endothelial cell transporter for lipoprotein lipase
Young, S. G., Davies, B. S. J., Voss, C. V., Gin, P., Weinstein, M. M., Tontonoz, P., Reue, K., Bensadoun, A., Fong, L. G., & Beigneux, A. P. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r018689 · Cited by 108 · cited 1×
“GPIHBP1, encoded by the GPIHBP1 gene, seizes LPL in the interstitial space (13, 14) and shuttles it across endothelial cells to the lumenal surface; it also tethers LPL to the capillary endothelium (15).”
BackgroundAngiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes
Dijk, W., Beigneux, A. P., Larsson, M., Bensadoun, A., Young, S. G., & Kersten, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m067363 · Cited by 103 · cited 2×
“(52) provide mechanistic information about multiple actions of ANGPTL4 to inhibit adipose-derived LPL, helping to explain the improved lipid profile and protection from CHD among carriers of loss-of-function variants.”
BackgroundApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100 · cited 1×
“There is also substantial evidence that apoC-III plays a role in hepatic TG-rich lipoprotein production (31).”
BackgroundHegele, R. A., Ban, M. R., Hsueh, N., Kennedy, B. A., Cao, H., Zou, G. Y., Anand, S., Yusuf, S., Huff, M. W., & Wang, J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp361 · Cited by 100 · cited 2×
“Homozygosity for the E2 isoform, in the context of additional genetic or nongenetic factors, can be associated with hyperlipidemia, characterized by increased plasma levels of chylomicron and VLDL remnants, associated with xanthomatosis and early atherosclerosis (26).”
BackgroundSelf-citationTalmud, P. J., Smart, M., Presswood, E., Cooper, J. A., Nicaud, V., Drenos, F., Palmen, J., Marmot, M. G., Boekholdt, S. M., Wareham, N. J., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.176917 · Cited by 94 · cited 1×
“Although earlier studies could not definitively tie this variant to cardioprotection (55), recent genetic findings clearly make this link (10, 53).”
BackgroundJohansen, C. T., Wang, J., McIntyre, A. D., Martins, R. A., Ban, M. R., Lanktree, M. B., Huff, M. W., Péterfy, M., Mehrabian, M., Lusis, A. J., et al. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.960864 · Cited by 93 · cited 1×
“with severe hypertriglyceridemia (24), but not with increased CVD risk.”
BackgroundSelf-citationLipase maturation factor 1: A lipase chaperone involved in lipid metabolism
Péterfy, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.006 · Cited by 85 · cited 1×
“gene for murine combined lipase deficiency (11, 12).”
BackgroundHuang, Y., Liu, X. Q., Rall, S. C., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17483 · Cited by 84 · cited 1×
“In this pathological state, E2-containing particles accumulate in plasma: increased plasma cholesterol in these patients results from impaired clearance of E2-bearing particles, while increased TG is caused by interference with LPL by E2 (27).”
BackgroundLipase maturation factor 1: structure and role in lipase folding and assembly
Doolittle, M. H., Ehrhardt, N., & Péterfy, M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833854c0 · Cited by 75 · cited 2×
“gene for murine combined lipase deficiency (11, 12).”
BackgroundCommon Genomic Variation in the APOC3 Promoter Associated With Variation in Plasma Lipoproteins
Hegele, R. A., Connelly, P. W., Hanley, A. J. G., Sun, F., Harris, S. B., & Zinman, B. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2753 · Cited by 74 · cited 1×
“elevated TG and reduced HDL cholesterol (38).”
Self-citationPathogenic classification of LPL gene variants reported to be associated with LPL deficiency
Rodrigues, R., Artieda, M., Tejedor, D., Martínez, A., Konstantinova, P. S., Petry, H., Meyer, C., Corzo, D., Sundgreen, C., Klör, H. U., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.015 · Cited by 51 · cited 2×
“The central nonredundant role of basal LPL mass and activity in directing intravascular hydrolysis of TG-rich lipoproteins is underscored by the causative role of very rare homozygous loss-of-function variants in the LPL gene in patients with severe hypertriglyceridemia (essentially chylomicronemia) and increased risk…”
BackgroundAdeyo, O., Goulbourne, C. N., Bensadoun, A., Beigneux, A. P., Fong, L. G., & Young, S. G. (2012) · Journal of Internal Medicine · doi:10.1111/joim.12003 · Cited by 48
JCL Roundtable: Hypertriglyceridemia due to defects in lipoprotein lipase function
Brown, W. V., Goldberg, I. J., & Young, S. G. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.009 · Cited by 19
Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18 · cited 1×
“Some liver-derived apoA-V is secreted into plasma and facilitates LPL-mediated TG hydrolysis, while another portion is recoverable intracellularly, in association with cytosolic lipid droplets (43).”
BackgroundLahiry, P., Cao, H., Ban, M. R., Pollex, R. L., Mamakeesick, M., Zinman, B., Harris, S. B., Hanley, A. J., Huff, M. W., Connelly, P. W., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p002014 · Cited by 17 · cited 1×
“seen only in North American indigenous people was associated with lower body mass index (19).”
BackgroundSelf-citationGerritsen, G., van der Hoogt, C. C., Schaap, F. G., Voshol, P. J., Kypreos, K. E., Maeda, N., Groen, A. K., Havekes, L. M., Rensen, P. C. N., & van Dijk, K. W. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800009-jlr200 · Cited by 13
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“Alipogene tiparvovec (Glybera; uniQure, Lexington, MA, USA) gene therapy for LPL deficiency was available in Europe until 2017, when the sponsor declined to renew market authorization.”
BackgroundInfluentialSelf-citationGenetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244
Self-citationThe interplay of factors in metabolic syndrome: understanding its roots and complexity
Islam, M. S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01019-y · Cited by 169
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“In patients with severe hypertriglyceridemia, atherosclerosis risk is increased among individuals who have a diffuse spectrum of large TG-rich chylomicron remnants (ie, polygenic chylomicronemia) but not among those with pure monogenic chylomicronemia.(74) Elevated TG levels are consistently associated with ASCVD in e…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Hegele, Robert A.
- ORCID
- Hegele, Robert A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 57
- Issue
- 9
- Pages
- 1601-1607
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC5003155
- OpenAlex
- W2475024711
- Cited by
- 31
- References
- 59
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1462 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Heart and Stroke Foundation of Canada (G-15-0009214)
- Genome Canada
- Canadian Institutes of Health Research (G-15-0009214)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- lipoprotein lipase, lipoprotein metabolism, triglyceride-rich lipoproteins, chylomicrons, VLDL, cardiovascular risk, insulin action, energy balance, body weight, genetic variants, monoglycerides
- MeSH terms
- Apolipoproteins, Cardiovascular System, Cardiovascular Physiological Phenomena, Lipoprotein Lipase, Phenotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.